

Click For [Full Prescribing Information](#), including **BOXED WARNING**, for
Bicillin® L-A (penicillin G benzathine injectable suspension)

Pfizer Inc.

275 North Field Drive
Lake Forest, IL 60045



January 21, 2026

**Availability Update for Bicillin® L-A
(penicillin G benzathine injectable suspension) Prefilled Syringes**

Dear Customer,

Pfizer remains committed to providing timely and transparent updates so that you can plan for patient care. This letter serves as a follow-up to our previous communications, including the August 21, 2025, availability update, regarding Bicillin® L-A (penicillin G benzathine injectable suspension) Prefilled Syringes.

Current Supply Status

At this time, Bicillin® L-A (penicillin G benzathine injectable suspension) Prefilled Syringes remain on allocation at the wholesaler level. Pfizer continues to ship limited quantities to wholesaler partners, and customers' ability to receive product is dependent on availability through normal wholesale channels. Based on current inventory and manufacturing projections, the estimated delivery and recovery timelines apply:

Unit of Sale NDC	Product Description	Estimated Next Delivery	Estimated Recovery
60793-0701-10	Bicillin® L-A (penicillin G benzathine injectable suspension) 1.2 million Units/2 mL (600,000 units/mL) Prefilled Syringe	July 2026	Q4 2026
60793-0702-10	Bicillin® L-A (penicillin G benzathine injectable suspension) 2.4 million Units/4 mL (600,000 units/mL) Prefilled Syringe	July 2026	Q4 2026
60793-0700-10	Bicillin® L-A (penicillin G benzathine injectable suspension) Pediatric 600,000 Units/mL Prefilled Syringe	December 2026	Q4 2026

We recognize the impact these allocation levels may have on care and continue to actively manage supply while progressing manufacturing and release activities.

Ordering and Medical Request Process

Customers should continue to source product through their authorized wholesalers when available. For situations in which product cannot be accessed through wholesale channels, Pfizer will continue to support access through its [Medical Request Process](#), which is limited to patients with confirmed congenital syphilis or those at risk of congenital syphilis, in alignment with CDC guidance.

Pfizer will continue to monitor supply closely and provide updates as additional information becomes available. Customers are encouraged to consult the [Availability Report](#) and [Medical Request Form](#) on [PfizerHospitalUS.com](#), or to contact their Pfizer Hospital & Biosimilars sales representative or health system director for the most current information.

Alternatively, the Supply Continuity Team can be contacted between 7 a.m. and 6 p.m. (CT) at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]). For medical inquiries, please contact Pfizer Medical Information at 1-800-438-1985.

Thank you,

Jacqueline Barr

Portfolio Director, Sterile Injectable Brands

U.S. Commercial, Global Hospital & Biosimilars